Open Access

Frontiers in Immunology

, volume 8

Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types

Kristina M. Ilieva ^{1, 2}

Anthony Cheung ^{1, 2}

Silvia Mele ¹

Giulia Chiaruttini ¹

Silvia Crescioli ¹

Merope Griffin ¹

Mano Nakamura ^{1, 3}

James F. Spicer ⁴

SOPHIA TSOKA ³

Katie E. Lacy ¹

Andrew N. J. Tutt ^{2, 5}

Sophia N Karagiannis ^{1, 2}

Hide authors affiliations Show authors affiliations: 5 affiliations

St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London & NIHR Biomedical Research Centre at Guy’s and St. Thomas’ Hospitals and King’s College London, Guy’s Hospital, United Kingdom |

Breast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, King’s College London, Guy’s Cancer Centre, United Kingdom |

Department of Informatics, Faculty of Natural and Mathematical Sciences, King’s College London, United Kingdom |

⁴

School of Cancer and Pharmaceutical Sciences, King’s College London, Guy’s Cancer Centre, United Kingdom |

⁵

Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, United Kingdom |

Publication type: Journal Article

Publication date: 2018-01-10

Frontiers Media S.A.

Frontiers in Immunology

scimago Q1

wos Q1

SJR: 1.941

CiteScore: 10.8

Impact factor: 5.9

ISSN: 16643224

DOI: 10.3389/fimmu.2017.01911

Copy DOI

PubMed ID: 29375561

Immunology

Immunology and Allergy

Abstract

Overexpression of the chondroitin sulphate proteoglycan 4 (CSPG4) has been associated with the pathology of multiple types of such as melanoma, breast cancer, squamous cell carcinoma, mesothelioma, neuroblastoma, adult and paediatric sarcomas, and some hematological cancers. CSPG4 has been reported to exhibit a role in the growth and survival as well as in the spreading and metastasis of tumor cells. CSPG4 is overexpressed in several malignant diseases, while it is thought to have restricted and low expression in normal tissues. Thus, CSPG4 has become the target of numerous anti-cancer treatment approaches, including monoclonal antibody-based therapies. This study reviews key potential anti-CSPG4 antibody and immune-based therapies and examines their direct anti-proliferative/metastatic and immune activating mechanisms of action.

Found

1 citation

Yagolovich Anne

🥼 🤝

PhD in Biological/biomedical sciences, lecturer

31 publications, 279 citations, 4 reviews

h-index: 10

Lomonosov Moscow State University

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences

Research interests

Apoptosis

Top-30

Journals

	2 4 6 8 10 12
Cancers	Cancers, 11, 9.82% Cancers 11 publications, 9.82%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 7, 6.25% International Journal of Molecular Sciences 7 publications, 6.25%
Frontiers in Immunology	Frontiers in Immunology, 5, 4.46% Frontiers in Immunology 5 publications, 4.46%
Nature Communications	Nature Communications, 3, 2.68% Nature Communications 3 publications, 2.68%
Carbohydrate Polymers	Carbohydrate Polymers, 3, 2.68% Carbohydrate Polymers 3 publications, 2.68%
Frontiers in Genetics	Frontiers in Genetics, 2, 1.79% Frontiers in Genetics 2 publications, 1.79%
Frontiers in Cell and Developmental Biology	Frontiers in Cell and Developmental Biology, 2, 1.79% Frontiers in Cell and Developmental Biology 2 publications, 1.79%
Scientific Reports	Scientific Reports, 2, 1.79% Scientific Reports 2 publications, 1.79%
Journal of Translational Medicine	Journal of Translational Medicine, 2, 1.79% Journal of Translational Medicine 2 publications, 1.79%
International Journal of Biological Macromolecules	International Journal of Biological Macromolecules, 2, 1.79% International Journal of Biological Macromolecules 2 publications, 1.79%
OncoImmunology	OncoImmunology, 2, 1.79% OncoImmunology 2 publications, 1.79%
Molecular Cancer Therapeutics	Molecular Cancer Therapeutics, 2, 1.79% Molecular Cancer Therapeutics 2 publications, 1.79%
Molecular Therapy	Molecular Therapy, 2, 1.79% Molecular Therapy 2 publications, 1.79%
Oncology Letters	Oncology Letters, 2, 1.79% Oncology Letters 2 publications, 1.79%
Journal of Experimental and Clinical Cancer Research	Journal of Experimental and Clinical Cancer Research, 2, 1.79% Journal of Experimental and Clinical Cancer Research 2 publications, 1.79%
Journal of Pathology	Journal of Pathology, 2, 1.79% Journal of Pathology 2 publications, 1.79%
Oncogene	Oncogene, 2, 1.79% Oncogene 2 publications, 1.79%
Current Medicinal Chemistry	Current Medicinal Chemistry, 1, 0.89% Current Medicinal Chemistry 1 publication, 0.89%
Thyroid	Thyroid, 1, 0.89% Thyroid 1 publication, 0.89%
Clinical Science	Clinical Science, 1, 0.89% Clinical Science 1 publication, 0.89%
Life	Life, 1, 0.89% Life 1 publication, 0.89%
Antibodies	Antibodies, 1, 0.89% Antibodies 1 publication, 0.89%
Cells	Cells, 1, 0.89% Cells 1 publication, 0.89%
Frontiers in Endocrinology	Frontiers in Endocrinology, 1, 0.89% Frontiers in Endocrinology 1 publication, 0.89%
Science China Life Sciences	Science China Life Sciences, 1, 0.89% Science China Life Sciences 1 publication, 0.89%
Journal of Ovarian Research	Journal of Ovarian Research, 1, 0.89% Journal of Ovarian Research 1 publication, 0.89%
Current Treatment Options in Oncology	Current Treatment Options in Oncology, 1, 0.89% Current Treatment Options in Oncology 1 publication, 0.89%
BioDrugs	BioDrugs, 1, 0.89% BioDrugs 1 publication, 0.89%
PLoS Biology	PLoS Biology, 1, 0.89% PLoS Biology 1 publication, 0.89%
	2 4 6 8 10 12

Publishers

	5 10 15 20 25
MDPI	MDPI, 25, 22.32% MDPI 25 publications, 22.32%
Springer Nature	Springer Nature, 23, 20.54% Springer Nature 23 publications, 20.54%
Elsevier	Elsevier, 16, 14.29% Elsevier 16 publications, 14.29%
Frontiers Media S.A.	Frontiers Media S.A., 12, 10.71% Frontiers Media S.A. 12 publications, 10.71%
Taylor & Francis	Taylor & Francis, 4, 3.57% Taylor & Francis 4 publications, 3.57%
Spandidos Publications	Spandidos Publications, 4, 3.57% Spandidos Publications 4 publications, 3.57%
Wiley	Wiley, 4, 3.57% Wiley 4 publications, 3.57%
Oxford University Press	Oxford University Press, 3, 2.68% Oxford University Press 3 publications, 2.68%
American Association for Cancer Research (AACR)	American Association for Cancer Research (AACR), 3, 2.68% American Association for Cancer Research (AACR) 3 publications, 2.68%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 2, 1.79% Public Library of Science (PLoS) 2 publications, 1.79%
Hindawi Limited	Hindawi Limited, 2, 1.79% Hindawi Limited 2 publications, 1.79%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 2, 1.79% Cold Spring Harbor Laboratory 2 publications, 1.79%
Bentham Science Publishers Ltd.	Bentham Science Publishers Ltd., 1, 0.89% Bentham Science Publishers Ltd. 1 publication, 0.89%
Mary Ann Liebert	Mary Ann Liebert, 1, 0.89% Mary Ann Liebert 1 publication, 0.89%
Portland Press	Portland Press, 1, 0.89% Portland Press 1 publication, 0.89%
Walter de Gruyter	Walter de Gruyter, 1, 0.89% Walter de Gruyter 1 publication, 0.89%
American Physiological Society	American Physiological Society, 1, 0.89% American Physiological Society 1 publication, 0.89%
Publishing House ABV Press	Publishing House ABV Press, 1, 0.89% Publishing House ABV Press 1 publication, 0.89%
Institute of Electrical and Electronics Engineers (IEEE)	Institute of Electrical and Electronics Engineers (IEEE), 1, 0.89% Institute of Electrical and Electronics Engineers (IEEE) 1 publication, 0.89%
Hans Publishers	Hans Publishers, 1, 0.89% Hans Publishers 1 publication, 0.89%
Japan Academy	Japan Academy, 1, 0.89% Japan Academy 1 publication, 0.89%
SciELO	SciELO, 1, 0.89% SciELO 1 publication, 0.89%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii	Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii, 1, 0.89% Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii 1 publication, 0.89%
	5 10 15 20 25

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

PDF

Metrics

112

Cite this

GOST |

Cite this

GOST Copy

Ilieva K. M. et al. Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types // Frontiers in Immunology. 2018. Vol. 8.

GOST all authors (up to 50) Copy

Ilieva K. M., Cheung A., Mele S., Chiaruttini G., Crescioli S., Griffin M., Nakamura M., Spicer J. F., TSOKA S., Lacy K. E., Tutt A. N. J., Karagiannis S. N. Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types // Frontiers in Immunology. 2018. Vol. 8.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.3389/fimmu.2017.01911

UR - https://doi.org/10.3389/fimmu.2017.01911

TI - Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types

T2 - Frontiers in Immunology

AU - Ilieva, Kristina M.

AU - Cheung, Anthony

AU - Mele, Silvia

AU - Chiaruttini, Giulia

AU - Crescioli, Silvia

AU - Griffin, Merope

AU - Nakamura, Mano

AU - Spicer, James F.

AU - TSOKA, SOPHIA

AU - Lacy, Katie E.

AU - Tutt, Andrew N. J.

AU - Karagiannis, Sophia N

PY - 2018

DA - 2018/01/10

PB - Frontiers Media S.A.

VL - 8

PMID - 29375561

SN - 1664-3224

ER -

BibTex

Cite this

BibTex (up to 50 authors) Copy

@article{2018_Ilieva,

author = {Kristina M. Ilieva and Anthony Cheung and Silvia Mele and Giulia Chiaruttini and Silvia Crescioli and Merope Griffin and Mano Nakamura and James F. Spicer and SOPHIA TSOKA and Katie E. Lacy and Andrew N. J. Tutt and Sophia N Karagiannis},

title = {Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types},

journal = {Frontiers in Immunology},

year = {2018},

volume = {8},

publisher = {Frontiers Media S.A.},

month = {jan},

url = {https://doi.org/10.3389/fimmu.2017.01911},

doi = {10.3389/fimmu.2017.01911}

}

Publisher

Frontiers Media S.A.

Journal

Frontiers in Immunology

scimago Q1

wos Q1

SJR

1.941

CiteScore

10.8

Impact factor

5.9

ISSN

16643224 (Electronic)